Background: Pancreatic mucinous cystic neoplasms (MCNs) are rare mucin-producing cystic tumours defined by the presence of ovarian-type stroma. MCNs have a malignant potential and thus surgery is frequently performed. The aim of this cohort study was to define better the criteria for surgical resection in patients with MCN. In multivariable analysis, raised carbohydrate antigen 19-9 (odds ratio (OR) 10⋅54, 95 per cent c.i. 2⋅85 to 218⋅23; P < 0⋅001), tumour size (OR 4⋅23, 3⋅02 to 11⋅03; P = 0⋅001), mural nodules (OR 3⋅55, 1⋅31 to 20⋅55; P = 0⋅002) and weight loss (OR 3⋅40, 2⋅34 to 12⋅34; P = 0⋅034) were independent factors predictive of malignant transformation.
Introduction
Mucinous cystic neoplasms (MCNs) are neoplastic cystic tumours of the pancreas that have the potential to evolve into an invasive cancer. They have been classified separately from intraductal papillary mucinous neoplasms (IPMNs) by the World Health Organization (WHO) since 1996 1 , and by the Armed Forces Institute of Pathology since 1997 2 . Pancreatic MCNs are defined as well demarcated cystic lesions, lined by a mucin-producing columnar epithelium overlying an ovarian-type stroma 1 . Although MCNs are relatively rare, the overall incidence of pancreatic cystic neoplasms is increasing 3 -5 . MCNs are estimated to account for 10-45 per cent of all resected pancreatic cysts 6, 7 .
Although MCNs are classified as neoplastic lesions 8 , their actual malignant potential remains uncertain, with rates of associated invasive cancer ranging from 0 to 34 per cent in the current literature 9 . Associated malignancy was substantially higher in older studies, but these series included many larger lesions and tumours classified before the latest WHO pathological criteria for MCN, so may have inadvertently incorporated a proportion of IPMNs, potentially explaining the higher rates of malignancy observed 10 . Recent publications 11 -17 from single centres have suggested that malignant transformation in MCN may actually be rare, especially when the tumours are small in size (less than 4 cm).
The current management of pancreatic cystic neoplasms is defined by a number of consensus guidelines, from the International Association of Pancreatology (IAP) 18 , the European expert consensus statement on cystic tumours of the pancreas 19 and the American Gastroenterological Association 20 . The IAP and European guidelines specifically mention the management of MCN, and both stipulate that where the diagnosis is certain and the patient is an operative candidate then surgical resection should be performed. Within the European consensus statement on cystic lesions of the pancreas there is a proviso that where the diagnosis is uncertain, and there are no associated worrisome features and the lesion is smaller than 4 cm, surveillance may be appropriate. However, to date very few studies have described the natural history of small MCNs to support this management strategy, and none has validated the current recommendation within the European guidelines.
As the guidelines for MCNs to date have primarily advocated surgical resection, few studies have described which worrisome features would predict malignant transformation if these lesions were to be surveyed. With the exception of a recent systematic review 21 and a single multi-institution US study 22 , worrisome features in MCN have been drawn from small single-centre experiences or extrapolated from findings in IPMN. Further large patient cohorts that have undergone careful classification and long-term follow-up are therefore needed to inform better the natural history and optimal criteria for surgical resection of these lesions.
The aim of this large multi-institution European study was to determine the rate of associated malignancy in resected MCNs, define which clinical and radiological features predict malignant transformation, and validate the management guidelines for MCNs proposed by the European consensus statement on pancreatic cystic neoplasms.
Methods

Setting and study design
This was a multicentre, retrospective, observational study from nine pancreatic centres from across Europe ( Table  S1 , supporting information). The study was conducted in accordance with STROBE guidelines 23 for observational studies.
Ethics
The study protocol was reviewed and ethical approval obtained from the local review board in each centre. In the UK, the Health Research Authority deemed the study to be primarily an audit of current practice and therefore formal ethical review was not required. The study protocol conforms to the ethical guidelines of the Declaration of Helsinki.
Inclusion and exclusion criteria
All consecutive patients with a histologically confirmed MCN of the pancreas resected between 1 January 2003 and 31 December 2015 in each participating centre were eligible for inclusion. Patients were identified though individual units' pancreatic cyst databases, multidisciplinary team meeting records and pathology records. After local review of the pathology report, any patient with an MCN without ovarian-type stroma was excluded from the study.
Data recorded
The medical records for each patient were reviewed in each centre, and the following information, where available, was recorded in the study spreadsheet: name of hospital, sex, age at diagnosis and medical history, ASA fitness grade, diabetes, smoking, previous pancreatic disease, previous cancer, and family history of cancer.
Any associated symptoms were also recorded; an MCN was defined as symptomatic when identified on imaging performed for the evaluation of abdominal or back pain, obstructive jaundice, acute/recurrent pancreatitis, or any documented history of recent weight loss. The results of the following preoperative blood tests, when undertaken, were recorded: amylase, serum carcinoembryonic antigen (CEA) (normal range below 4⋅0 ng/ml) and serum carbohydrate antigen (CA) 19-9 (normal range less than 37 units/ml) levels.
Radiological data recorded included type of scan: ultrasound imaging, CT, MRI, endoscopic ultrasonography (EUS) and fine-needle aspiration (FNA). From the cross-sectional imaging (CT or MRI), the following features were recorded: lesion size (maximum dimension), location and number of cystic lesions, presence of a solid component (mural nodules, solid component, calcification of the cyst or the wall, wall thickening), presence of septation, features of acute or chronic pancreatitis, and dilatation of the main pancreatic duct to more than 6 mm (upstream of the cyst) or biliary tree dilatation. For patients undergoing EUS-FNA, cytology and cyst fluid biochemistry (CEA and amylase) results were also recorded.
Operative details recorded included date of surgery and type of resection, adverse postoperative events (according to Clavien-Dindo grading 24 ), 30-day mortality, final histology findings, length of follow-up (time from surgery to the last MCN-related or other relevant outpatient appointment), follow-up imaging data and evidence of recurrence.
Histopathological analysis
The diagnosis of an MCN was confirmed locally in each centre. The presence of ovarian-type stroma was considered mandatory for diagnosis and inclusion in the study. Where the original report was inconclusive, and in all men, a second review by an experienced local pancreatic pathologist was undertaken to confirm the diagnosis. Dysplasia was classified in accordance with the most aggressive histological epithelial changes as defined by the WHO classification system 8 . Tumours were graded as having low-or intermediate-grade dysplasia, high-grade dysplasia (HGD) including carcinoma in situ, and malignant when invasive carcinoma was present 7 .
Statistical analysis
All statistical analyses were performed using SPSS ® version 22.0 (IBM, Armonk, New York, USA). χ 2 or Fisher's exact tests were applied for analysis of categorical variables. Median (range) values were used for continuous variables. The non-parametric Mann-Whitney U test was used to compare continuous variables. Multiple logistic regression models were used to identify independent factors for malignant transformation. Long-term survival was analysed using Kaplan-Meier log rank analysis. All tests were two-tailed and P < 0⋅050 was considered statistically significant.
Results
A total of 211 patients with a histologically confirmed surgically resected MCN were included in the study ( Table 1) . Sixty-three per cent of the patients were symptomatic, and in the remainder the diagnosis was made incidentally during abdominal cross-sectional imaging performed for other reasons. Investigation was done with CT in 187 patients (88⋅6 per cent) and with MRI in the remainder. Fifty-eight patients (28⋅5 per cent) had both CT and MRI. On preoperative imaging, the median tumour size was 55 (range mm. An MCN was suspected clinically in 49⋅7 per cent (73 of 147 patients), an IPMN in 11⋅6 per cent (17 of 147) and the diagnosis remained uncertain in 38⋅8 per cent (57 of 147). Cyst features are presented in Table 1 .
In addition to cross-sectional imaging by CT or MRI, 141 (66⋅8 per cent) of the 211 patients had EUS, and FNA was performed in 118 (55⋅9 per cent). Cytology had a sensitivity, specificity, positive predictive value and negative predictive value for malignant transformation of 66⋅7, 98⋅1, 66⋅7, 98⋅1 per cent respectively.
A distal pancreatectomy was performed in the majority of patients ( Table 1 ). The 30-day mortality rate was 0⋅9 per cent, and the 30-day morbidity rate was 37⋅9 per cent, classified as Clavien-Dindo grade I in 10⋅4 per cent, grade Table 2) .
The rate of invasive cancer correlated with increasing tumour size (Fig. 1a) . In lesions of 12 cm or more, the rate of invasive cancer was 30 per cent (7 of 23 patients), compared with just 5 per cent (1 of 22) in lesions of 3⋅0-3⋅9 cm and 6 per cent (2 of 36) in lesions of less than 3⋅0 cm. Five cases of malignant transformation were seen in cysts smaller than 4 cm in size, and all were associated with symptoms or features of concern on imaging ( Table  S2 , supporting information). When stratified by sex, the malignancy rate for lesions smaller than 3⋅0 cm in women decreased to 3 per cent (1 of 32 women) (HGD also 3 per cent), compared with 25 per cent in men (1 of 4 men) (HGD also 25 per cent) (Fig. 1b,c) . All patients with malignant lesions or HGD, regardless of tumour size, had symptoms or one or more features of concern on cross-sectional imaging.
In univariable analysis, the presence of symptoms, previous pancreatitis, jaundice, raised CA19-9 level, recent weight loss, tumour size and mural nodules were significant risk factors predictive of invasive cancer ( Table 3) . In multivariable analysis, raised CA19-9 level, mural nodules, weight loss and tumour size remained independent factors of malignant transformation. The model was a good predictor of malignant transformation with a Nagelkerke R 2 value of 0⋅7. Median survival for patients with a malignant MCN was 44 (range 0-167) months; 12 patients died during follow-up, ten from disease recurrence. A non-significant but notable difference in survival was observed between men and women (P = 0⋅134) (Fig. 2) .
Discussion
In this large cohort of patients, resected after the introduction of the new pathological classification of MCN, the overall rate of associated invasive cancer was low: 16⋅1 per cent, compared with up to 34 per cent in some earlier publications 9 . Rates of HGD were lower than in other single-centre series 13, 14, 17 at 6⋅2 per cent, but similar to the rate found in a recent multicentre study from North America 22 .
In clinical practice, differentiation of MCN from other unicystic and oligocystic tumours (branch-duct IPMN and serous cystadenoma) remains a significant challenge, as, to date, features that predict invasive malignancy in MCN have been poorly characterized and often overlap with those of other cystic lesions of the pancreas 25 . When pancreatic cysts are small, the diagnosis can be especially difficult as many of the typical radiological features (communication with the main pancreatic duct in the case of branch-duct IPMNs) are not present.
The preoperative uncertainty in defining these lesions was clearly reflected in this study, with less than half of MCNs being classified correctly before resection. Current guidelines are clear and consistent when the diagnosis of MCN is certain, recommending surgical resection in all patients. However, when the preoperative diagnosis is less clear, as in a large proportion of patients in this study, the European guidelines 19 suggest that, if the lesion is small in size (less than 4 cm) and without worrisome features, a period of surveillance may be appropriate to define the diagnosis better before surgery. However, few studies have explored the natural history of MCNs to support the safety of this proposed management strategy.
Over the past three decades, the size at which MCNs are detected has decreased 21 . Given that features of concern are often absent in small lesions, cyst diameter has remained the most important radiological predictor of malignant transformation. The MCN size at which patients should be referred for surgical resection remains uncertain. In this large cohort study, invasive cancer occurred in 6 per cent of lesions less than 4 cm (2 of 36) and in 5 per cent of those smaller than 3 cm (1 of 22). In the five cases of invasive cancer in lesions smaller than 4 cm, as well as all cases of cancer or HGD in this study, at least one preoperative worrisome feature was present to prompt surgical resection. When stratified by sex, the rate of associated invasive cancer in women with lesions smaller than 3 cm was 3 per cent (1 of 32) and in lesions of 3⋅0-3⋅9 cm was 0 per cent. Although these retrospective data were drawn from surgically resected patients and need to be confirmed by prospective surveillance studies, the findings do suggest that the conservative management of indeterminate cystic lesions which are probably MCNs, is feasible, as advocated by the European guidelines 19 , particularly in small lesions (less than 4 cm) occurring in women without worrisome features.
MCNs differ from other pancreatic cystic neoplasms by occurring predominantly in women. Whether MCNs, defined by the presence of ovarian-type stroma, can even occur in men has been debated 26 , although a number of cases in men have been described 13, 14, 17 . In the present study, with careful pathological characterization, just 4⋅3 per cent of MCNs occurred in men, one of the lowest rates reported to date. Rates of invasive cancer and HGD were more common in men than in women, and appeared to occur at an earlier stage when the lesions were still small in size. However, numbers are too small to arrive at definite conclusions.
In the multivariable analysis, in addition to tumour size, a raised CA19-9 level and mural nodules were also independent predictors of invasive cancer. This supports the findings of other studies that also found CA19-9 14, 22 and the presence of a solid component or mural nodule 11, 14, 16, 17, 25, 27 to be reliable predictors of invasive malignancy in MCN.
The survival of patients with a malignant MCN is superior to that of patients with pancreatic ductal adenocarcinoma 7 . A non-significant difference in survival was also observed between men and women in the present study, which, although unexpected, perhaps further supports the more aggressive behaviour of MCN observed in men in this cohort and others 22 . For other female-predominant pancreatic cystic neoplasms, such as solid pseudopapillary tumours, men have also been observed to have a poorer prognosis 28 . All cases of malignancy were seen solely in MCNs with symptoms or worrisome features, regardless of tumour size. A raised CA19-9 level, a solid component, weight loss or large tumour size (4 cm or above) predicted malignant transformation in these lesions. Therefore, for small indeterminate lesions with no symptoms or features of concern, a more conservative approach is potentially feasible, as advocated in the European consensus statement on cystic tumours of the pancreas 19 .
This study has several strengths: it analyses a large cohort of carefully characterized patients with a pathologically confirmed MCN, with ovarian-type stroma present in all cases. The data set includes comprehensive demographic, clinical, radiological, surgical, pathological and follow-up information, which has allowed better definition of features that may predict malignant transformation. Potential limitations include that most patients were from tertiary referral centres, so the proportion of high-risk lesions and malignant cases may be higher. Much lower incidences of associated malignancy have been reported from large community-based and surveillance cohorts of pancreatic cystic neoplasms 29 . However, without being able to define MCN lesions pathologically, it would be impossible to undertake such a study. Some patients included in the study may have been included in previously reported case series.
